Yuan Tian Phones & Addresses
-
3757 Temple City Blvd, Rosemead, CA 91770
-
1957 Strathmore Ave, San Gabriel, CA 91776 (626) 569-9015
-
112 Loftus Dr, San Gabriel, CA 91776 (626) 927-9157
-
714 Hellman Ave, Monterey Park, CA 91755 (626) 288-6829 (626) 569-9015
-
El Monte, CA
-
Los Angeles, CA
Business Records
Name / Title
Company / Classification
Phones & Addresses
President
Drip Tip Master Inc
2385 S Hacienda Blvd, Whittier, CA 91745
FANCY & FUNKY LLC
Sinoedge Consulting Group LLC
Consulting - Acounting, Taxes, and Finan · Consulting Finance Accounting & Taxes · Business Consulting Services
Consulting - Acounting, Taxes, and Finan · Consulting Finance Accounting & Taxes · Business Consulting Services
600 N Rosemead Blvd, Pasadena, CA 91107
4815 Daleridge Rd, La Canada, CA 91011
4815 Daleridge Rd, La Canada, CA 91011
President
HAPPY FAMILY VEGETARIAN GROUP INC
5118 Walnut Grv Ave, San Gabriel, CA 91776
Publications
Us Patents
Protein Expression Analysis For Breast Cancer Prognosis And Treatment
View pageUS Patent:
20200278353, Sep 3, 2020
Filed:
Sep 26, 2018
Appl. No.:
16/650482
Inventors:
- Culver City CA, US
Fabiola CECCHI - Potomac MD, US
Yuan TIAN - Culver City CA, US
Christina YAU - San Francisco CA, US
Christopher SZETO - Culver City CA, US
Todd HEMBROUGH - Gaithersburg MD, US
Stephen Charles BENZ - Santa Cruz CA, US
Fabiola CECCHI - Potomac MD, US
Yuan TIAN - Culver City CA, US
Christina YAU - San Francisco CA, US
Christopher SZETO - Culver City CA, US
Todd HEMBROUGH - Gaithersburg MD, US
Stephen Charles BENZ - Santa Cruz CA, US
International Classification:
G01N 33/68
A61K 31/704
A61P 35/00
A61K 31/704
A61P 35/00
Abstract:
Methods are provided for identifying whether a cancer patient, and especially a breast cancer patient, will be responsive to treatment. Specified TOPO2A, IDO1 and/or p16 fragment peptides are precisely detected and quantitated by SRM-mass spectrometry directly in cancer cells collected from tumor tissue that was obtained from a cancer patient and compared to reference levels in order to determine if the cancer patient will positively respond to treatment. Measurement of TOPO2A provides a direct indication of whether a patient will respond to anthracycline-containing therapy, and, in particular, neoadjuvant anthracycline-containing therapy. Quantitative levels of IDO1 and p16 are compared to reference levels in order to determine if a breast cancer patient will likely demonstrate a pathologically complete response (pCR) of cancer after cancer therapy treatment, irrespective of the chosen treatment.